SIRPA and nonpapillary renal cell carcinoma: Interestingly, the co-expression of SIRPA and CD47 was significantly associated with poor prognosis for ccRCC patients (HR = 1.39, P = 0.032) (Fig. 7h), while high expression of CD47 or SIRPA only slightly contribute to poor prognosis of ccRCC patients (HR = 1.34, P = 0.054 for CD47; HR = 1.33, P = 0.078 for SIRPA) (Supplementary Fig. 7e, f).